Symphogen A/S is developing antibody mixtures intended to prevent the development of resistance in cancer. The company announced its first cancer deal this month with Merck KGaA, which will help the biotech expand its pipeline with an eye on niche products it can develop itself.

Merck sees the deal as an opportunity to retain worldwide rights to a product with the potential to be more efficacious than its cancer mAb, Erbitux cetuximab.